(-)-Epigallocatechin-3-Gallate (EGCG) plays a therapeutic role in lithium-pilocarpine-induced epilepsy through the inhibition of the Toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) signaling pathway (Qu et al., 2019). This evidence concerns the gene TLR4 and epilepsy.